Autologous stem cell transplantation in patients who object to a blood transfusion: contribution of new pharmacological haematopoiesis support. (öffnet neues Fenster)

Al-Nawakil C, Quarre MC, Heshmati F, Deau B, Park S, Dreyfus F, Bouscary D, Tamburini J.

Quelle‎: Br J Haematol 2013;161(5):738-40.

Indiziert‎: PubMed 23480574

DOI‎: 10.1111/bjh.12284

https://www.ncbi.nlm.nih.gov/pubmed/23480574 (öffnet neues Fenster)

A multicenter study of romiplostim for chemotherapy-induced thrombocytopenia in solid tumors and hematologic malignancies. (öffnet neues Fenster)

Al-Samkari H, Parnes AD, Goodarzi K, Weitzman JI, Connors JM, Kuter DJ

Quelle‎: Haematologica 2021;106(4):1148-57.

Indiziert‎: PubMed 32499239

DOI‎: 10.3324/haematol.2020.251900

https://www.ncbi.nlm.nih.gov/pubmed/32499239 (öffnet neues Fenster)

The effect of interleukin 11 on thrombocytopenia associated with tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia. (öffnet neues Fenster)

Aribi A, Kantarjian H, Koller C, Thomas D, Faderl S, Garcia-Manero G, Cortes J.

Quelle‎: Cancer 2008;113(6):1338-43.

Indiziert‎: PubMed 18629842

DOI‎: 10.1002/cncr.23718

https://www.ncbi.nlm.nih.gov/pubmed/18629842 (öffnet neues Fenster)

Romiplostim efficacy in an acute myeloid leukemia patient with transfusion refractory thrombocytopenia. (öffnet neues Fenster)

Berthelot-Richer M, Boilard B, Morin A, Bolduc B, Beauregard P, Kotb R.

Quelle‎: Transfusion 2012;52(4):739-41.

Indiziert‎: PubMed 22082044

DOI‎: 10.1111/j.1537-2995.2011.03382.x

https://www.ncbi.nlm.nih.gov/pubmed/22082044 (öffnet neues Fenster)

The role of interleukin-11 to prevent chemotherapy-induced thrombocytopenia in patients with solid tumors, lymphoma, acute myeloid leukemia and bone marrow failure syndromes. (öffnet neues Fenster)

Bhatia M, Davenport V, Cairo MS.

Quelle‎: Leuk Lymphoma 2007;48(1):9-15.

Indiziert‎: PubMed 17325843

DOI‎: 10.1080/10428190600909115

https://www.ncbi.nlm.nih.gov/pubmed/17325843 (öffnet neues Fenster)

Results of a phase I dose escalation study of eltrombopag in patients with advanced soft tissue sarcoma receiving doxorubicin and ifosfamide. (öffnet neues Fenster)

Chawla SP, Staddon A, Hendifar A, Messam CA, Patwardhan R, Kamel YM.

Quelle‎: BMC Cancer 2013;13:121.

Indiziert‎: PubMed 23497336

DOI‎: 10.1186/1471-2407-13-121

https://www.ncbi.nlm.nih.gov/pubmed/23497336 (öffnet neues Fenster)

Efficacy of romiplostim in the treatment of chemotherapy induced thrombocytopenia (CIT) in a patient with mantle cell lymphoma. (öffnet neues Fenster)

Demeter J, Istenes I, Fodor A, Paksi M, Dombi P, Valasinyószki E, Csomor J, Matolcsy A, Nagy ZG.

Quelle‎: Pathol Oncol Res 2011;17(1):141-3.

Indiziert‎: PubMed 20628840

DOI‎: 10.1007/s12253-010-9276-4

https://www.ncbi.nlm.nih.gov/pubmed/20628840 (öffnet neues Fenster)

Eltrombopag for radiation-induced thrombocytopenia in a glioblastoma patient. (öffnet neues Fenster)

Duic JP, Grewal J, McConie K, Staszewski H, Haas J, Kesari S.

Quelle‎: J Neurooncol 2012;106(2):427-9.

Indiziert‎: PubMed 21833801

DOI‎: 10.1007/s11060-011-0675-5

https://www.ncbi.nlm.nih.gov/pubmed/21833801 (öffnet neues Fenster)

Recombinant human interleukin 11 and bacterial infection in patients with haematological malignant disease undergoing chemotherapy: a double-blind placebo-controlled randomised trial. (öffnet neues Fenster)

Ellis M, Zwaan F, Hedström U, Poynton C, Kristensen J, Jumaa P, Wassell J, al-Ramadi B.

Quelle‎: Lancet 2003;361(9354):275-80.

Indiziert‎: PubMed 12559860

https://www.ncbi.nlm.nih.gov/pubmed/12559860 (öffnet neues Fenster)

Autologous stem-cell transplantation without hematopoietic support for the treatment of hematologic malignancies in Jehovah's Witnesses. (öffnet neues Fenster)

Ford PA, Grant SJ, Mick R, Keck G.

Quelle‎: J Clin Oncol 2015;33(15):1674-9.

Indiziert‎: PubMed 25870085

DOI‎: 10.1200/JCO.2014.57.9912

https://www.ncbi.nlm.nih.gov/pubmed/25870085 (öffnet neues Fenster)

Effect of avatrombopag in the management of severe and refractory chemotherapy-induced thrombocytopenia (CIT) in patients with solid tumors. (öffnet neues Fenster)

Gao Y, Liu Q, Shen Y, Li Y, Shao K, Ye B, Shen Y, Zhou Y, Wu D

Quelle‎: Platelets. 2022 3;33(7):1024-1030.

Indiziert‎: PubMed 35040375

DOI‎: 10.1080/09537104.2022.2026910

https://pubmed.ncbi.nlm.nih.gov/35040375/ (öffnet neues Fenster)

Results of a randomized, double-blind study of romiplostim versus placebo in patients with low/intermediate-1-risk myelodysplastic syndrome and thrombocytopenia. (öffnet neues Fenster)

Giagounidis A, Mufti GJ, Fenaux P, Sekeres MA, Szer J, Platzbecker U, Kuendgen A, Gaidano G, Wiktor-Jedrzejczak W, Hu K, Woodard P, Yang AS, Kantarjian HM.

Quelle‎: Cancer 2014;120(12):1838-46.

Indiziert‎: PubMed 24706489

DOI‎: 10.1002/cncr.28663

https://www.ncbi.nlm.nih.gov/pubmed/24706489 (öffnet neues Fenster)

A randomized controlled trial of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving decitabine. (öffnet neues Fenster)

Greenberg PL, Garcia-Manero G, Moore M, Damon L, Roboz G, Hu K, Yang AS, Franklin J.

Quelle‎: Leuk Lymphoma 2013;54(2):321-8.

Indiziert‎: PubMed 22906162

DOI‎: 10.3109/10428194.2012.713477

https://www.ncbi.nlm.nih.gov/pubmed/22906162 (öffnet neues Fenster)

Thrombopoietin-receptor agonists in haematological disorders: the Danish experience. (öffnet neues Fenster)

Gudbrandsdottir S, Frederiksen H, Hasselbalch H.

Quelle‎: Platelets 2012;23(6):423-9.

Indiziert‎: PubMed 22185370

DOI‎: 10.3109/09537104.2011.634931

https://www.ncbi.nlm.nih.gov/pubmed/22185370 (öffnet neues Fenster)

Recombinant human thrombopoietin promotes platelet engraftment after haploidentical hematopoietic stem cell transplantation: a prospective randomized controlled trial. (öffnet neues Fenster)

Han TT, Xu LP, Liu DH, Liu KY, Wang FR, Wang Y, Yan CH, Chen YH, Sun YQ, Ji Y, Wang JZ, Zhang XH, Huang XJ.

Quelle‎: Ann Hematol 2015;94(1):117-28.

Indiziert‎: PubMed 25069650

DOI‎: 10.1007/s00277-014-2158-1

https://www.ncbi.nlm.nih.gov/pubmed/25069650 (öffnet neues Fenster)

The non-peptide thrombopoietin receptor agonist eltrombopag stimulates megakaryopoiesis in bone marrow cells from patients with relapsed multiple myeloma. (öffnet neues Fenster)

Jeong JY, Levine MS, Abayasekara N, Berliner N, Laubach J, Vanasse GJ.

Quelle‎: J Hematol Oncol 2015;8:37.

Indiziert‎: PubMed 25886818

DOI‎: 10.1186/s13045-015-0136-2

https://www.ncbi.nlm.nih.gov/pubmed/25886818 (öffnet neues Fenster)

Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia. (öffnet neues Fenster)

Kantarjian H, Fenaux P, Sekeres MA, Becker PS, Boruchov A, Bowen D, Hellstrom-Lindberg E, Larson RA, Lyons RM, Muus P, Shammo J, Siegel R, Hu K, Franklin J, Berger DP.

Quelle‎: J Clin Oncol 2010;28(3):437-44.

Indiziert‎: PubMed 20008626

DOI‎: 10.1200/JCO.2009.24.7999

https://www.ncbi.nlm.nih.gov/pubmed/20008626 (öffnet neues Fenster)

The use of simple patient blood management strategies as an alternative to platelet and red cell transfusion in autologous stem cell transplant. (öffnet neues Fenster)

Locantore-Ford P, Grant SJ, Keck G.

Quelle‎: Blood 2013;122(21):2140.

https://www.bloodjournal.org/content/122/21/2140 (öffnet neues Fenster)

The effect of recombinant human erythropoietin on platelet counts is strongly modulated by the adequacy of iron supply. (öffnet neues Fenster)

Loo M, Beguin Y.

Quelle‎: Blood 1999;93(10):3286-93.

Indiziert‎: PubMed 10233880

https://www.ncbi.nlm.nih.gov/pubmed/10233880 (öffnet neues Fenster)

A single center experience with romiplostim for the management of chemotherapy-induced thrombocytopenia. (öffnet neues Fenster)

Miao J, Leblebjian H, Scullion B, Parnes A

Quelle‎: Am J Hematol 2018;93(4):E86-E88.

Indiziert‎: PubMed 29274130

DOI‎: 10.1002/ajh.25022

https://www.ncbi.nlm.nih.gov/pubmed/29274130 (öffnet neues Fenster)

Pharmacological therapies to minimise platelet transfusion. (öffnet neues Fenster)

Norfolk DR, Seghatchian J.

Quelle‎: Transfus Sci 2000;22(3):149-53.

Indiziert‎: PubMed 10831916

https://www.ncbi.nlm.nih.gov/pubmed/10831916 (öffnet neues Fenster)

Romiplostim for management of chemotherapy-induced thrombocytopenia. (öffnet neues Fenster)

Parameswaran R, Lunning M, Mantha S, Devlin S, Hamilton A, Schwartz G, Soff G.

Quelle‎: Support Care Cancer 2014;22(5):1217-22.

Indiziert‎: PubMed 24414994

DOI‎: 10.1007/s00520-013-2074-2

https://www.ncbi.nlm.nih.gov/pubmed/24414994 (öffnet neues Fenster)

Eltrombopag for the treatment of thrombocytopenia in patients with malignant and non-malignant hematologic disorders. (öffnet neues Fenster)

Pathak S, Roth M, Verma A, Steidl U.

Quelle‎: Expert Opin Drug Metab Toxicol 2013;9(12):1667-75.

Indiziert‎: PubMed 24215532

DOI‎: 10.1517/17425255.2013.858119

https://www.ncbi.nlm.nih.gov/pubmed/24215532 (öffnet neues Fenster)

High-dose chemotherapy without transfusion for Philadelphia chromosome negative B-cell acute lymphoblastic leukemia in two Jehovah's Witnesses patients: a feasible option in the age of hematopoietic growth factors. (öffnet neues Fenster)

Perol L, Grignano E, Contejean A, Gastaud L, Legoff M, Franchi P, Deau-Fischer B, Willems L, Bouscary D, Tamburini J

Quelle‎: Leuk Lymphoma. 2019;60(9):2324-7.

Indiziert‎: PubMed 30773115

DOI‎: 10.1080/10428194.2019.1577414

https://www.ncbi.nlm.nih.gov/pubmed/30773115 (öffnet neues Fenster)

Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial. (öffnet neues Fenster)

Platzbecker U, Wong RS, Verma A, Abboud C, Araujo S, Chiou TJ, Feigert J, Yeh SP, Götze K, Gorin NC, Greenberg P, Kambhampati S, Kim YJ, Lee JH, Lyons R, Ruggeri M, Santini V, Cheng G, Jang JH, Chen CY, Johnson B, Bennett J, Mannino F, Kamel YM, Stone N, Dougherty S, Chan G, Giagounidis A.

Quelle‎: Lancet Haematol 2015;2(10):e417-26.

Indiziert‎: PubMed 26686043

https://www.ncbi.nlm.nih.gov/pubmed/26686043 (öffnet neues Fenster)

Romiplostim for delayed platelet recovery and secondary thrombocytopenia following allogeneic stem cell transplantation. (öffnet neues Fenster)

Poon LM, Di Stasi A, Popat U, Champlin RE, Ciurea SO.

Quelle‎: Am J Blood Res 2013;3(3):260-4.

Indiziert‎: PubMed 23997988

https://www.ncbi.nlm.nih.gov/pubmed/23997988 (öffnet neues Fenster)

Safety and efficacy of eltrombopag in post-hematopoietic stem cell transplantation (HSCT) thrombocytopenia. (öffnet neues Fenster)

Raut SS, Shah SA, Sharanangat VV, Shah KM, Patel KA, Anand AS, Talati SS, Panchal HP, Patel AA, Parikh SK, Shukla SN.

Quelle‎: Indian J Hematol Blood Transfus 2015;31(4):413-5.

Indiziert‎: PubMed 26306064

DOI‎: 10.1007/s12288-014-0491-0

https://www.ncbi.nlm.nih.gov/pubmed/26306064 (öffnet neues Fenster)

Identifying drugs that cause acute thrombocytopenia: an analysis using 3 distinct methods. (öffnet neues Fenster)

Reese JA, Li X, Hauben M, Aster RH, Bougie DW, Curtis BR, George JN, Vesely SK.

Quelle‎: Blood 2010;116(12):2127-33.

Indiziert‎: PubMed 20530792

DOI‎: 10.1182/blood-2010-03-276691

https://www.ncbi.nlm.nih.gov/pubmed/20530792 (öffnet neues Fenster)

Eltrombopag inhibits the proliferation of leukemia cells via reduction of intracellular iron and induction of differentiation. (öffnet neues Fenster)

Roth M, Will B, Simkin G, Narayanagari S, Barreyro L, Bartholdy B, Tamari R, Mitsiades CS, Verma A, Steidl U.

Quelle‎: Blood 2012;120(2):386-94.

Indiziert‎: PubMed 22627766

DOI‎: 10.1182/blood-2011-12-399667

https://www.ncbi.nlm.nih.gov/pubmed/22627766 (öffnet neues Fenster)

Subcutaneous or intravenous administration of romiplostim in thrombocytopenic patients with lower risk myelodysplastic syndromes. (öffnet neues Fenster)

Sekeres MA, Kantarjian H, Fenaux P, Becker P, Boruchov A, Guerci-Bresler A, Hu K, Franklin J, Wang YM, Berger D.

Quelle‎: Cancer 2011;117(5):992-1000.

Indiziert‎: PubMed 20945323

DOI‎: 10.1002/cncr.25545

https://www.ncbi.nlm.nih.gov/pubmed/20945323 (öffnet neues Fenster)

Romiplostim treatment of chemotherapy-induced thrombocytopenia. (öffnet neues Fenster)

Soff GA, Miao Y, Bendheim G, Batista J, Mones JV, Parameswaran R, Wilkins CR, Devlin SM, Abou-Alfa GK, Cercek A, Kemeny NE, Sarasohn DM, Mantha S

Quelle‎: J Clin Oncol 2019;37(31):2892-8.

Indiziert‎: PubMed 31545663

DOI‎: 10.1200/JCO.18.01931

https://www.ncbi.nlm.nih.gov/pubmed/31545663 (öffnet neues Fenster)

Effects of erythropoietin on platelet reactivity and thrombopoiesis in humans. (öffnet neues Fenster)

Stohlawetz PJ, Dzirlo L, Hergovich N, Lackner E, Mensik C, Eichler HG, Kabrna E, Geissler K, Jilma B.

Quelle‎: Blood 2000;95(9):2983-9.

Indiziert‎: PubMed 10779449

https://www.ncbi.nlm.nih.gov/pubmed/10779449 (öffnet neues Fenster)

A pilot phase I dose finding safety study of the thrombopoietin-receptor agonist, eltrombopag, in patients with myelodysplastic syndrome treated with azacitidine. (öffnet neues Fenster)

Svensson T, Chowdhury O, Garelius H, Lorenz F, Saft L, Jacobsen SE, Hellström-Lindberg E, Cherif H.

Quelle‎: Eur J Haematol 2014;93(5):439-45.

Indiziert‎: PubMed 24853277

DOI‎: 10.1111/ejh.12383

https://www.ncbi.nlm.nih.gov/pubmed/24853277 (öffnet neues Fenster)

Eltrombopag for treatment of thrombocytopenia after allogeneic hematopoietic cell transplantation. (öffnet neues Fenster)

Tanaka T, Inamoto Y, Yamashita T, Fuji S, Okinaka K, Kurosawa S, Kim SW, Tanosaki R, Fukuda T.

Quelle‎: Biol Blood Marrow Transplant 2016;22(5):919-24.

Indiziert‎: PubMed 26785333

DOI‎: 10.1016/j.bbmt.2016.01.018

https://www.ncbi.nlm.nih.gov/pubmed/26785333 (öffnet neues Fenster)

Low-dose interleukin-11 in patients with bone marrow failure: update of the M. D. Anderson Cancer Center experience. (öffnet neues Fenster)

Tsimberidou AM, Giles FJ, Khouri I, Bueso-Ramos C, Pilat S, Thomas DA, Cortes J, Kurzrock R.

Quelle‎: Ann Oncol 2005;16(1):139-45.

Indiziert‎: PubMed 15598951

DOI‎: 10.1093/annonc/mdi007

https://www.ncbi.nlm.nih.gov/pubmed/15598951 (öffnet neues Fenster)

A randomized, double-blind, placebo-controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate-1 risk myelodysplastic syndrome receiving lenalidomide. (öffnet neues Fenster)

Wang ES, Lyons RM, Larson RA, Gandhi S, Liu D, Matei C, Scott B, Hu K, Yang AS.

Quelle‎: J Hematol Oncol 2012;5:71.

Indiziert‎: PubMed 23190430

DOI‎: 10.1186/1756-8722-5-71

https://www.ncbi.nlm.nih.gov/pubmed/23190430 (öffnet neues Fenster)

Romiplostim for chemotherapy-induced thrombocytopenia: efficacy and safety of extended use. (öffnet neues Fenster)

Wilkins CR, Ortiz J, Gilbert LJ, Yin S, Mones JV, Parameswaran R, Mantha S, Soff GA

Quelle‎: Res Pract Thromb Haemost. 2022;6(3):e12701.

Indiziert‎: PubMed 35582038

DOI‎: 10.1002/rth2.12701

https://pubmed.ncbi.nlm.nih.gov/35582038/ (öffnet neues Fenster)

Effect of the nonpeptide thrombopoietin receptor agonist eltrombopag on bone marrow cells from patients with acute myeloid leukemia and myelodysplastic syndrome. (öffnet neues Fenster)

Will B, Kawahara M, Luciano JP, Bruns I, Parekh S, Erickson-Miller CL, Aivado MA, Verma A, Steidl U.

Quelle‎: Blood 2009;114(18):3899-908.

Indiziert‎: PubMed 19710504

DOI‎: 10.1182/blood-2009-04-219493

https://www.ncbi.nlm.nih.gov/pubmed/19710504 (öffnet neues Fenster)